[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657395":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":11,"studyPopulation":11,"armGroups":33,"interventions":53,"overallOfficials":63,"centralContacts":68,"locations":77,"responsibleParty":91,"collaborators":11,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":95,"sex":101,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":11,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":124,"whyStopped":11,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"Verve Therapeutics, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percent Change from Baseline in LDL-C",null,"Baseline, Day 90",[14,16,18,20,22],{"measure":10,"description":11,"timeFrame":15},"Baseline to End of Study (up to Day 365)",{"measure":17,"description":11,"timeFrame":15},"Percent Change from Baseline in Circulating Proprotein Convertase Subtilisin\u002FKexin Type 9 (PCSK9)",{"measure":19,"description":11,"timeFrame":15},"Percent Change from Baseline Total Cholesterol",{"measure":21,"description":11,"timeFrame":15},"Percent Change from Baseline in Non-High-Density Lipoprotein Cholesterol (non-HDL-C)",{"measure":23,"description":11,"timeFrame":15},"Percent Change from Baseline in Apolipoprotein B",{"allocation":25,"interventionModel":26,"interventionModelDescription":11,"primaryPurpose":27,"observationalModel":11,"timePerspective":11,"maskingInfo":28},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":29,"maskingDescription":11,"whoMasked":30},"DOUBLE",[31,32],"PARTICIPANT","INVESTIGATOR",[34,40,44,47],{"label":35,"type":36,"description":37,"interventionNames":38},"VERVE-102 Dose 1","EXPERIMENTAL","Participants will receive a single dose of VERVE-102 intravenously (IV)",[39],"Drug: VERVE-102",{"label":41,"type":36,"description":42,"interventionNames":43},"VERVE-102 Dose 2","Participants will receive a single dose of VERVE-102 IV",[39],{"label":45,"type":36,"description":42,"interventionNames":46},"VERVE-102 Dose 3",[39],{"label":48,"type":49,"description":50,"interventionNames":51},"Placebo","PLACEBO_COMPARATOR","Participants will receive a single dose of placebo IV",[52],"Drug: Placebo",[54,61],{"type":55,"name":56,"description":57,"armGroupLabels":58,"otherNames":59},"DRUG","VERVE-102","Administered IV",[35,41,45],[60],"LY4636581",{"type":55,"name":48,"description":57,"armGroupLabels":62,"otherNames":11},[48],[64],{"name":65,"affiliation":66,"role":67},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","Eli Lilly and Company","STUDY_DIRECTOR",[69,74],{"name":70,"role":71,"phone":72,"phoneExt":11,"email":73},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","317-615-4559","LillyTrials@Lilly.com",{"name":75,"role":71,"phone":11,"phoneExt":11,"email":76},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[78],{"facility":79,"status":11,"city":80,"state":81,"zip":82,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":90,"contacts":11},"Epic Medical Research","DeSoto","Texas","75115","United States","US",{"type":86,"coordinates":87},"Point",[88,89],-96.85695,32.58986,{"lat":89,"lon":88},{"type":92,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100657395","phase-2-a-study-of-verve-102-ly4636581-in-adults-with-or-at-high-risk-for-cardiovascular-disease-100657395",false,"NCT07839936","A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of VERVE-102, a One-Time Dose Gene Editing Medicine, in Adults With or at High Risk for Atherosclerotic Cardiovascular Disease (ASCVD) Who Require Additional Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering","HEART-3","Inclusion Criteria:\n\n* Established atherosclerotic cardiovascular disease (ASCVD) and\u002For at a high risk of ASCVD\n\nExclusion Criteria:\n\n* History of confirmed or suspected homozygous familial hypercholesterolemia (HoFH)\n* Chronic liver disease\n* Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe","ALL","18 Years","70 Years",{"count":105,"type":106},175,"ESTIMATED","INTERVENTIONAL",[109],"PHASE2","The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.",[112,113,114],"Atherosclerosis","Cardiovascular Disease","Hypercholesterolemia",[116,117,118,119,120,121,122,123],"Heterozygous Familial Hypercholesterolemia","LDL cholesterol","High cholesterol","Cardiovascular risk factors","Coronary Artery Disease","Heart attack","Stroke","Base editing","NOT_YET_RECRUITING","2026-09-18",{"date":127,"type":128},"2026-09-24","ACTUAL",{"date":130,"type":106},"2026-10",{"date":132,"type":106},"2030-03",{"name":5,"class":6},1]